PrecisionLife and Ovation to Launch GLP-1 DNA Test by 2026

April 15, 2026
PrecisionLife and Ovation.io have agreed to co-develop laboratory tests and a consumer DNA test to predict individual responses to GLP-1 drugs, with commercial launch planned for the second half of 2026.

PrecisionLife and Ovation.io have entered into a collaboration to develop laboratory and consumer genetic tests focused on GLP-1 drug response, announced in a press release. The companies aim to launch a consumer DNA test in the second half of 2026 to help individuals understand their likely safety, efficacy, and tolerability profiles for GLP-1 receptor agonist therapies.

The collaboration builds on PrecisionLife’s analysis of Ovation’s GLP-1 dataset, which identified distinct biomarkers for glycemic control and weight loss. These findings will be validated across additional datasets over the next six months, including studies on semaglutide and tirzepatide. The partners plan to use these insights to support clinical trials and inform reimbursement decisions for payors.

The companies also intend to co-develop laboratory developed tests (LDTs) for use in clinical trials to identify strong responders in new therapeutic areas. Discussions with pharmaceutical partners are underway to integrate these stratification tools into drug development and post-marketing studies.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like Enterprise AI Brief, Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Enterprise AI Healthcare & Life Sciences AI AI Brief AI Brief (X)

More from: Enterprise

04/15
OpenAI Expands Agents SDK With Sandboxing and Harness Features
04/15
Rockefeller Foundation Commits $10 Million to IRC for AI-Powered Humanitarian Innovation
04/15
REALLY Introduces AI Voice Clone for Phone Calls and Tasks
04/15
Knox Systems Achieves FedRAMP High Authorization with FEMA Partnership
04/15
Ascendion Named Market Leader in Agentic Services by HFS Research

More from: Life Sciences

04/15
EmpiRx Health Launches Infusion Therapy Management Solution to Cut Costs
04/15
Wobble Genomics to Present Full-Length mRNA Sequencing Data at AACR 2026
04/15
Cepheid and Oxford Nanopore Expand Partnership for Infectious Disease Genomics
04/14
Axxess AGILE 2026 Conference to Focus on Responsible AI in Home Care
04/14
Xtalks to Host Webinar on AI and Molecular Advances in Hematologic Cancer Drug Development

Subscribe to Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Market report

2025 Generative AI in Professional Services Report

Thomson Reuters

This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.

Read more

You May Also Like